Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, ...

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints ...

A physical therapist may: In this Q&A, Iversen talks about how physical therapy can benefit people with psoriatic arthritis and what you need to know about finding the right physical therapist for ...

Main findings - Early symptoms of psoriatic arthritis (PsA) often persist for some time before the condition is diagnosed and ...

Korea: A recent retrospective cohort study published in the Journal of the American Academy of Dermatology explored the link ...

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

Patients with psoriatic arthritis experience longer delays in diagnosis, receive less intensive therapy, and show less improvement in disease activity than matched patients with rheumatoid arthritis.

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...

A new study published in the journal of Arthritis & Rheumatology found with high-resolution peripheral quantitative CT ...